4D Molecular Therapeutics

  • About
    • Company Overview
    • Purpose AND Strategy
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • Technology
    • GENETIC MEDICINES
    • Conventional Vectors
    • 4DMT Therapeutic Vector Evolution
    • SCIENTIFIC PRESENTATIONS
  • Product Pipeline
    • Pipeline Overview
    • Ophthalmology
    • Cardiology
    • Pulmonology
  • Patients
    • Overview
    • Clinical Trials
      • XLRP 4D-125
      • XLRP Natural History
      • CHM 4D-110
      • Wet AMD 4D-150
      • Fabry 4D-310
      • CF 4D-710
    • Advocacy Partners
    • Patient Stories
    • Resources
  • Investors
    • Overview
    • Events and Presentations
    • Press Releases
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Careers and Culture
    • Overview and Openings
    • Competitive Compensation
    • BENEFITS, BALANCE and WELL-BEING
    • GROWTH AND DEVELOPMENT
    • CULTURE and COMMUNITY
  • Home
  • Terms of Use
Menu

1 billion possibilities
for a cure

Boldly Innovating to Unlock
the Full Potential of Genetic Medicines
for Countless Patients

VECTOR &
PROMOTER
TECHNOLOGY THAT
DELIVERS

More

LEARN MORE
ABOUT OUR
clinical TRIALS

More

A DIVERSE
PRODUCT
PIPELINE

More

PATIENT
ADVOCACY AND
PERSONAL STORIES

More

In The News

February 2023

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

more

January 2023

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

more

See how we’re innovating to unlock the full potential of genetic medicines

Learn what differentiates our optimized, proprietary, targeted vectors

Share Linkedin Facebook
  • About
    • Company Overview
    • Purpose AND Strategy
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • Technology
    • GENETIC MEDICINES
    • Conventional Vectors
    • 4DMT Therapeutic Vector Evolution
    • SCIENTIFIC PRESENTATIONS
  • Product Pipeline
    • Pipeline Overview
    • Ophthalmology
    • Cardiology
    • Pulmonology
  • Patients
    • Overview
    • Clinical Trials
      • XLRP 4D-125
      • XLRP Natural History
      • CHM 4D-110
      • Wet AMD 4D-150
      • Fabry 4D-310
      • CF 4D-710
    • Advocacy Partners
    • Patient Stories
    • Resources
  • Investors
    • Overview
    • Events and Presentations
    • Press Releases
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Careers and Culture
    • Overview and Openings
    • Competitive Compensation
    • BENEFITS, BALANCE and WELL-BEING
    • GROWTH AND DEVELOPMENT
    • CULTURE and COMMUNITY
  • Home
  • Terms of Use
© 2023 4D Molecular Therapeutics, All Rights Reserved